The denial of Terumo's motion to dismiss is a routine procedural step that keeps the patent infringement case alive. The next material event is the Markman hearing on January 28, 2027, where claim construction will shape the scope of the asserted patents. Monitor for any settlement discussions or summary judgment motions following claim construction.
Price Chart
Executive Summary
The District of Colorado denied Terumo BCT's motion to dismiss Haemonetics' patent infringement claims for patent-ineligibility under 35 U.S.C. § 101. The court adopted the magistrate's recommendation that Haemonetics plausibly alleged patent-eligible subject matter, allowing the case to proceed to claim construction. This is an interlocutory procedural ruling that keeps the case alive but does not resolve liability or damages.
Court Ruling Details
Key Facts
- Haemonetics sued Terumo BCT for patent infringement related to plasma collection systems
- Terumo moved to dismiss counts III, IV, VI-IX on patent-eligibility grounds under 35 U.S.C. § 101
- Magistrate Judge Prose recommended denial of the motion; the district court adopted that recommendation
- The court overruled Haemonetics' objections to intermediate findings (abstract idea determination and representative claim selection)
- A Markman (claim construction) hearing is set for January 28, 2027
- No damages were awarded; no injunction was issued
Financial Impact
No financial impact stated in the ruling. The case continues toward claim construction.
Risk Factors
- If claim construction narrows Haemonetics' patent claims, Terumo may renew its § 101 challenge or seek summary judgment of non-infringement
- Litigation costs will continue to accrue for both parties through discovery and claim construction
Investment Themes
Documents Analyzed
This report is based on 1 court opinion.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-9efdd5a1f5-HAE |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | Institutional Cluster | $117.11 $116.16 | ▼ −0.81% | ▲ +0.37% | $119.19 (+1.78%) |
Oct 19, 2026 7d ago | Press Release | $118.21 $117.11 | ▼ −0.93% | ▼ −1.46% | $119.19 (+0.83%) |
Oct 12, 2026 14d ago | Institutional Cluster | $122.06 $121.72 | ▼ −0.28% | ▼ −0.27% | $119.19 (−2.35%) |
Oct 8, 2026 18d ago | 8-K | $119.47 $118.69 | ▼ −0.65% | ▼ −1.25% | $119.19 (−0.23%) |
Sep 30, 2026 26d ago | Press Release | $104.37 $104.68 | ▲ +0.30% | ▼ −0.44% | $119.19 (+14.20%) |
Sep 30, 2026 26d ago | Court Ruling | $104.37 $104.68 | ▲ +0.30% | ▼ −0.44% | $119.19 (+14.20%) |
Aug 18, 2026 9w ago | 8-K | $104.65 $108.41 | ▲ +3.59% | ▲ +3.38% | $119.19 (+13.89%) |
Jun 9, 2026 19w ago | DEFA14A | $78.80 $79.84 | ▲ +1.32% | ▼ −0.38% | $119.19 (+51.26%) |
Jun 5, 2026 20w ago | 8-K | $71.28 $74.88 | ▲ +5.05% | ▲ +4.82% | $119.19 (+67.21%) |
May 7, 2026 24w ago | 8-K | $54.37 $55.12 | ▲ +1.38% | ▲ +0.55% | $119.19 (+119.22%) |
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers